Clinical Trial Update: Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a Technetium-99m labeled PSMA-targeted radiopharmaceutical, BQ0413, for molecular imaging in prostate cancer. The study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• BQ0413 (Technetium-99m labeled PSMA-targeted radiopharmaceutical)

Snippet

Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED